The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children
Makandjou-Ola Eusebio, Tomasz Grzelewski, Miroslawa Pietruczuk, Beata Lewandowska and Iwona Stelmach
Affiliation: Department of Pediatrics and Allergy, N Copernicus Hospital, 62 Pabianicka Street, 93-513, Lodz, Poland.
Despite the continuous increase in the prevalence of asthma in the most underdeveloped parts of the world, nowadays, we can generally speak of a better understanding and management of this disease. The remarkable role played by the inflammatory process in asthmatic patients is well known. The aim of most asthma guidelines is to suppress inflammatory process with a combination of anti-inflammatory drugs and immunotherapy. The management of asthma in children is a challenge because of their inability to express warning signs and seek medical attention in a timely manner. Unlike adults, asthmatic children must rely on their parents or caregivers for the administration of asthma medications. This inability to carry and self-administer asthma drugs may increase the risk of non-compliance. Glucocorticosteroids, the most important drugs for patients with asthma, are associated with an increased level of side effects and compliance issues mostly in children. In an attempt to solve that dilemma, emphasis is being placed on the modification of current management tactics and the introduction of other drugs. This review presents more recent patent therapies for the management of asthma in children.
Keywords: Glucocorticosteroids, asthma,, children, patents, immunotherapy, ICS, GR, chemokines, TNF-, GM-CSF, IL-5, IL-4, IL-13, HDAC2, hsp70, GREs, PIV3, oxidative stress, ADA, DHEA, BAED, BAET, ADP, ATP, CNS, DPCPX, SOD, Eosinophils, mAb, CCR3, Eotaxin-1, Ap-1, NFB, CAT-213
Rights & PermissionsPrintExport